Literature DB >> 33521892

The Excess Costs of Depression and the Influence of Sociodemographic and Socioeconomic Factors: Results from the German Health Interview and Examination Survey for Adults (DEGS).

Christian Brettschneider1, Alexander Konnopka1, Hannah König2, Alexander Rommel3, Julia Thom3, Christian Schmidt3, Hans-Helmut König1.   

Abstract

INTRODUCTION: The aim of this study was to estimate excess costs of depression in Germany and to examine the influence of sociodemographic and socioeconomic determinants.
METHODS: Annual excess costs of depression per patient were estimated for the year 2019 by comparing survey data of individuals with and without self-reported medically diagnosed depression, representative for the German population aged 18-79 years. Differences between individuals with depression (n = 223) and without depression (n = 4540) were adjusted using entropy balancing. Excess costs were estimated using generalized linear model regression with a gamma distribution and log-link function. We estimated direct (inpatient, outpatient, medication) and indirect (sick leave, early retirement) excess costs. Subgroup analyses by social determinants were conducted for sex, age, socioeconomic status, first-generation or second-generation migrants, partnership, and social support.
RESULTS: Total annual excess costs of depression amounted to €5047 (95% confidence interval [CI] 3214-6880) per patient. Indirect excess costs amounted to €2835 (1566-4103) and were higher than direct excess costs (€2212 [1083-3341]). Outpatient (€498), inpatient (€1345), early retirement (€1686), and sick leave (€1149) excess costs were statistically significant, while medication (€370) excess costs were not. Regarding social determinants, total excess costs were highest in the younger age groups (€7955 for 18-29-year-olds, €9560 for 30-44-year-olds), whereas total excess costs were lowest for the oldest age group (€2168 for 65+) and first-generation or second-generation migrants (€1820).
CONCLUSIONS: Depression was associated with high excess costs that varied by social determinants. Considerable differences between the socioeconomic and sociodemographic subgroups need further clarification as they point to specific treatment barriers as well as varying treatment needs.

Entities:  

Year:  2021        PMID: 33521892     DOI: 10.1007/s40273-021-01000-1

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  42 in total

1.  Ratio of means for analyzing continuous outcomes in meta-analysis performed as well as mean difference methods.

Authors:  Jan O Friedrich; Neill K J Adhikari; Joseph Beyene
Journal:  J Clin Epidemiol       Date:  2011-05       Impact factor: 6.437

2.  Excess health care costs of late-life depression - Results of the AgeMooDe study.

Authors:  Jens-Oliver Bock; Christian Brettschneider; Siegfried Weyerer; Jochen Werle; Michael Wagner; Wolfgang Maier; Martin Scherer; Hanna Kaduszkiewicz; Birgitt Wiese; Lilia Moor; Janine Stein; Steffi G Riedel-Heller; Hans-Helmut König
Journal:  J Affect Disord       Date:  2016-04-12       Impact factor: 4.839

3.  Prevalence and correlates of DSM-IV-TR major depressive disorder, self-reported diagnosed depression and current depressive symptoms among adults in Germany.

Authors:  Ulrike E Maske; Amanda K Buttery; Katja Beesdo-Baum; Steffi Riedel-Heller; Ulfert Hapke; Markus A Busch
Journal:  J Affect Disord       Date:  2015-10-24       Impact factor: 4.839

4.  Direct costs associated with depression in old age in Germany.

Authors:  Melanie Luppa; Sven Heinrich; Herbert Matschinger; Hagen Sandholzer; Matthias C Angermeyer; Hans-Helmut König; Steffi G Riedel-Heller
Journal:  J Affect Disord       Date:  2007-06-12       Impact factor: 4.839

5.  Impact of depression on health care utilization and costs among multimorbid patients--from the MultiCare Cohort Study.

Authors:  Jens-Oliver Bock; Melanie Luppa; Christian Brettschneider; Steffi Riedel-Heller; Horst Bickel; Angela Fuchs; Jochen Gensichen; Wolfgang Maier; Karola Mergenthal; Ingmar Schäfer; Gerhard Schön; Siegfried Weyerer; Birgitt Wiese; Hendrik van den Bussche; Martin Scherer; Hans-Helmut König
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

6.  Time trends in depression prevalence and health-related correlates: results from population-based surveys in Germany 1997-1999 vs. 2009-2012.

Authors:  Julia Bretschneider; Silke Janitza; Frank Jacobi; Julia Thom; Ulfert Hapke; Tobias Kurth; Ulrike E Maske
Journal:  BMC Psychiatry       Date:  2018-12-20       Impact factor: 3.630

7.  The excess costs of depression: a systematic review and meta-analysis.

Authors:  H König; H-H König; A Konnopka
Journal:  Epidemiol Psychiatr Sci       Date:  2019-04-05       Impact factor: 7.818

8.  Health costs in patients treated for depression, in patients with depressive symptoms treated for another chronic disorder, and in non-depressed patients: a two-year prospective cohort study in anthroposophic outpatient settings.

Authors:  Harald J Hamre; Claudia M Witt; Anja Glockmann; Renatus Ziegler; Gunver S Kienle; Stefan N Willich; Helmut Kiene
Journal:  Eur J Health Econ       Date:  2010-02

9.  The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study.

Authors:  Jan O Friedrich; Neill K J Adhikari; Joseph Beyene
Journal:  BMC Med Res Methodol       Date:  2008-05-21       Impact factor: 4.615

10.  Global patterns of workplace productivity for people with depression: absenteeism and presenteeism costs across eight diverse countries.

Authors:  S Evans-Lacko; M Knapp
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-09-26       Impact factor: 4.328

View more
  3 in total

1.  Excess costs of mental disorders by level of severity.

Authors:  Hannah König; Hans-Helmut König; Jürgen Gallinat; Martin Lambert; Anne Karow; Judith Peth; Holger Schulz; Alexander Konnopka
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2022-05-31       Impact factor: 4.328

2.  The NEVERMIND e-health system in the treatment of depressive symptoms among patients with severe somatic conditions: A multicentre, pragmatic randomised controlled trial.

Authors:  Vladimir Carli; Nuhamin Gebrewold Petros; Gergö Hadlaczky; Tereza Vitcheva; Paola Berchialla; Silvia Bianchi; Sara Carletto; Eirini Christinaki; Luca Citi; Sérgio Dinis; Claudio Gentili; Vera Geraldes; Lorena Giovinazzo; Sergio Gonzalez-Martinez; Björn Meyer; Luca Ostacoli; Manuel Ottaviano; Silvia Ouakinin; Tasos Papastylianou; Rita Paradiso; Riccardo Poli; Isabel Rocha; Carmen Settanta; Enzo Pasquale Scilingo; Gaetano Valenza
Journal:  EClinicalMedicine       Date:  2022-05-06

3.  Lipid Biomarkers in Depression: Does Antidepressant Therapy Have an Impact?

Authors:  Fidelis Christin Stuchtey; Andrea Block; Francis Osei; Pia-Maria Wippert
Journal:  Healthcare (Basel)       Date:  2022-02-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.